Please login to the form below

Not currently logged in
Email:
Password:

palbociclib

This page shows the latest palbociclib news and features for those working in and with pharma, biotech and healthcare.

FDA backs earlier use of Lilly’s breast cancer drug Verzenio

FDA backs earlier use of Lilly’s breast cancer drug Verzenio

The pharma company reckons Verzenio has the potential to be a best-in-class drug that can mount a strong challenge to Ibrance (palbociclib - which grew 46% to $3.1bn last

Latest news

More from news
Approximately 7 fully matching, plus 39 partially matching documents found.

Latest Intelligence

  • Engaging the digital healthcare professional Engaging the digital healthcare professional

    When NICE, the UK policymaker for health spending, rejected Pfizer’s breast cancer drug palbociclib for routine funding on the NHS in February, it tweeted the news and invited comments on ... Weeks later, following the NICE consultation period, the

  • Pharma deals during August 2013 Pharma deals during August 2013

    Palbociclib, which is the result of an early partnership with Pfizer and now being developed by Pfizer, is in phase III trials for advanced breast cancer and certain haematologic malignancies. ... If approved, Onyx will receive an 8 per cent royalty on

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Pharma and free medicines: a different perspective

    The cost of a full course of treatment with palbociclib is approximately £80, 000. ... Therefore, it will be interesting to see the final ruling of NICE on palbociclib.

  • Synergy Vision

    Pfizer have recently announced that they will provide the breast cancer drug, palbociclib, free of charge to patients.

More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics